Chinese Journal of Blood Purification ›› 2026, Vol. 25 ›› Issue (02): 156-159.doi: 10.3969/j.issn.1671-4091.2026.02.015

Previous Articles     Next Articles

Uremic tumoral calcinosis: pathophysiological mechanisms and advances in clinical management

MO Yu-yi, LU Jun, LIN Jing-tian, HUANG Hai-ting   

  1. 1 Graduate School, and 2 Admission and Career Services Guidance Center, Youjiang Medical University for Nationalities, Baise 533000, China; 3 Department of Nephrology, the Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, China; 4 Key Laboratory of Medical Research Basic Guarantee for Immune- Related Diseases Research of Guangxi (Cultivation), Baise 533000, China
  • Received:2025-07-18 Revised:2025-10-10 Online:2026-02-12 Published:2026-02-02
  • Contact: 533000 百色,3右江民族医学院附属医院肾内科;533000 百色,4广西免疫相关性疾病研究医学科研基础保障重点(培育)实验室 E-mail:hhtwsw123@126.com

Abstract: Uremic tumoral calcinosis (UTC) is a rare complication of end-stage renal disease, characterized by painless calcium salt deposits around large joints. Its core driving factor is elevated serum phosphate and calcium-phosphate product. Diagnosis requires a combination of dialysis history, clinical manifestations, imaging examinations, and laboratory indicators including serum calcium, phosphate, parathyroid hormone, and alkaline phosphatase. The therapeutic goal is to jointly control serum phosphate, serum calcium, and mineral-bone metabolism. Major approaches include non-calcium-based phosphate binders, low-calcium dialysis, parathyroidectomy, kidney transplantation, and lesion excision. Due to the lack of large-scale controlled studies, the optimal management strategy for UTC remains to be further validated

Key words: Uremic tumoral calcinosis, End-stage renal disease, Soft tissue calcification, Secondary hyperparathyroidism, Calcium-phosphorus product

CLC Number: